# US 8,614,090 B2 · Astrovirus species

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,614,090 B2
- Document ID: US8614090B2
- Status: Granted
- Kind: B2
- Application number: 12/859,068
- Filed: 2010-08-18
- Published: 2011-02-24
- Granted: 2013-12-24
- Earliest claimed: 2009-08-19
- Assignees: Blood Systems, Inc.
- Applicants: Eric Delwart; Amit Kapoor; Li Linlin
- Inventors: Eric Delwart; Amit Kapoor; Li Linlin
- Web page: https://patentgrep.com/patent/US8614090B2

## CPC

- C12Q 1/70: involving virus or bacteriophage {(immunoassay for viruses G01N33/56983)}
- A61P 31/14: for RNA viruses
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2770/12022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/12051: Methods of production or purification of viral material
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are sequences of the genomes and encoded proteins of new astrovirus species, and variants thereof. Also provided are methods of detecting the new astrovirus species and diagnosing astrovirus infection, methods of treating or preventing astrovirus infection, and methods for identifying anti-astrovirus compounds. Provided are two new astrovirus species named HMOAstV-A and HMOAstV-B, and both are distantly related to known astroviruses. Also provided is a new method of classifying astroviruses, where there are three groups of human astroviruses, including HAstV, AstV-MLB, and HMOAstV.

## Claims

### Claim 1

A recombinant vector comprising an operative promoter and a heterologous nucleic acid molecule comprising:
a) A sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:5, or the full-length complement thereof,
b) A sequence comprising at least 50, 100, 150 contiguous nucleotides of SEQ ID NO:1, SEQ ID NO:5, or the full-length complement thereof, or
c) A sequence having at least 75% identity to SEQ ID NO:1, SEQ ID NO:5, or a full-length complement thereof.

### Claim 2 (depends on 1)

The recombinant vector of claim 1, wherein the nucleic acid molecule comprises at least 50, 100 or 150 contiguous nucleotides of SEQ ID NO:1, SEQ ID NO:5, or the full-length complement thereof.

### Claim 3 (depends on 1)

The recombinant vector of claim 1, wherein the sequence is at least 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO:1, SEQ ID NO:5, or the full-length complement thereof.

### Claim 4 (depends on 1)

An isolated host cell comprising the recombinant vector of claim 1.

### Claim 5

A method of detecting an astrovirus nucleic acid comprising:
(a) contacting a sample suspected of containing an astrovirus nucleic acid with a nucleic acid molecule comprising at least 50, 100 or 150 contiguous nucleotides of SEQ ID NO:1, SEQ ID NO:5, or the full-length complement thereof; and (b) detecting the presence or absence of hybridization.

### Claim 6

A method of detecting an astrovirus nucleic acid comprising:
(a) amplifying the nucleic acid of a sample suspected of containing an astrovirus nucleic acid with at least one nucleic acid molecule comprising at least 50, 100 or 150 contiguous nucleotides of SEQ ID NO:1, SEQ ID NO:5, or the full-length complement thereof, to produce an amplification product; and
(b) detecting the presence of an amplification product, thereby detecting the presence of the astrovirus nucleic acid.

### Claim 7

A kit for detecting an astrovirus nucleic acid comprising a detectable label attached to an isolated nucleic acid molecule comprising at least 50, 100 or 150 contiguous nucleotides of SEQ ID NO:1, SEQ ID NO:5, or the full-length complement thereof.

### Claim 8

A method of assaying for an anti-astrovirus compound comprising:
(a) contacting a sample containing an astrovirus comprising a nucleotide sequence having at least 75% identity to SEQ ID NO:1, SEQ ID NO:5, or a full-length complement thereof, with a test compound; and
(b) determining whether the test compound inhibits astrovirus replication, wherein inhibition of astrovirus replication indicates that the test compound is an anti-astrovirus compound.